Wolverine
20 mg
€ 65,00
per vialComing soonWolverine — 20 mg total per research vial: TB-500 10 mg + BPC-157 10 mg. For laboratory research only; not for human or veterinary use.
- Reference
- MVP / 008
- Strength
- 20 mg
- Availability
- Coming soon
- Handling
- Store cool and dry, away from light. Laboratory handling only.
- Shipping
- PostNL within the Netherlands, € 4,99 per order
Specification
For research only. Not for human use.
Key research areas
- Dual-peptide interaction research (TB-500, BPC-157)
- Tendon-cell biology and FAK–paxillin signalling
- Cell migration across complementary pathways
- Cytoskeletal organisation studies
- Blend-versus-single-component comparison
Potential benefits observed in research
- Pairs two of the most-studied tissue-response peptides in one formulation.
- BPC-157 component is linked to tendon-cell migration and survival findings.
- TB-500 component is associated with actin-related motility research.
- Enables direct study of potential synergy between two repair-pathway compounds.
Reported observations from published studies under controlled conditions. They do not establish the safety, quality or performance of this research material.
Research documentation
Wolverine — 20 mg
Wolverine combines TB-500 10 mg and BPC-157 10 mg, providing a stated total of 20 mg per vial. BPC-157 is a synthetic peptide investigated in laboratory and animal studies of cell migration, survival and tissue responses to injury. Tendon-cell research has examined associated FAK–paxillin signalling, which helps coordinate cell attachment and movement. TB-500 is a name used in thymosin beta-4 fragment research; its precise sequence and chemical form must be established before interpreting molecular findings. The blend is scientifically interesting as a potential subject for comparing peptide interactions with individual-component responses.
Key Research Areas
- Cell migration
- tendon-cell biology
- cellular signalling
- peptide interactions
Those separate research findings do not demonstrate additive effects, accelerated recovery or therapeutic efficacy for Wolverine. Clinical benefit and safety are not established for this MVP formulation. BPC-157 research; TB-500 scientific review.
For research purposes only. Not for human consumption or therapeutic use.
